Keybank National Association OH Cuts Holdings in Kenvue Inc. $KVUE

Keybank National Association OH decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,884,962 shares of the company’s stock after selling 88,448 shares during the period. Keybank National Association OH owned approximately 0.25% of Kenvue worth $102,242,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KVUE. Renaissance Capital LLC grew its position in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC grew its position in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares in the last quarter. Arlington Partners LLC purchased a new position in Kenvue in the second quarter worth about $2,110,000. Cornell Pochily Investment Advisors Inc. grew its position in Kenvue by 144.6% in the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after acquiring an additional 19,609 shares in the last quarter. Finally, IFP Advisors Inc grew its position in Kenvue by 25.3% in the first quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after acquiring an additional 3,081 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $14.26 on Thursday. The firm has a market cap of $27.37 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 2.09 and a beta of 0.72. The company’s 50 day moving average is $17.50 and its 200 day moving average is $20.63. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $14.05 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue’s revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 5.8%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s payout ratio is currently 112.16%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on KVUE shares. Bank of America dropped their price target on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Citigroup dropped their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. UBS Group dropped their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a research report on Tuesday. Finally, Barclays decreased their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.17.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.